Facile synthesis of multifunctional Fe3O4@SiO2n@Au magneto-plasmonic nanoparticles for MR/CT dual imaging and photothermal therapy

Facile synthesis of multifunctional Fe3O4@SiO2n@Au magneto-plasmonic nanoparticles for MR/CT dual imaging and photothermal therapy
复制标题

轻松合成用于MR/CT双重成像和光热治疗的多功能Fe3O4@SiO(2)n@Au磁等离子体纳米粒子

DOI:
10.1039/c7ra00925a
复制
发表时间:
2017-01-01
期刊:
影响因子:
3.9
通讯作者:
Zhang, Yun
Zhang, Yun
中科院分区:
化学3区
文献类型:
--
作者:
Hou, Xuemei;Wang, Xuandong;Zhang, Yun

文献摘要

被引文献

相似文献

磁等离子体纳米粒子具有优异的磁、光激活等离子体特性,在癌症诊断和治疗中显示出巨大的潜力。然而,将这两种成分结合在一个纳米颗粒中仍然是一个巨大的挑战。在这项工作中,我们开发了一种简单的方法来合成Fe3O4@SiO2@GNSs-PEG (PMGNSs)纳米颗粒的单分散和均匀治疗剂。所合成的PMGNSs由超顺磁性Fe3O4内核、二氧化硅中间层和外包覆金纳米壳组成,尺寸分布均匀,小于100 nm。它已被证明在不同浓度下具有优异的磁共振(MR)和计算机断层扫描(CT)成像对比能力。同时,在所合成的PMGNSs中,在808 nm激光以2 W cm(-2)照射10 min, 160 μ g ml(-1)浓度下,经过5次激光开/关循环后,其光热性能无明显变化,稳定性高,光热转换能力高,温度升高40℃。此外,体外光热治疗HePG2癌细胞的能力也得到了证实。
Magneto-plasmonic nanoparticles have exhibited great potential in cancer diagnosis and therapy because of their excellent magnetic and optically activable plasmonic properties. However, it is still a great challenge to combine these two components in one single-nanoparticle. In this work, we developed a facile method to synthesize monodispersed and uniform theranostic agents of Fe3O4@SiO2@GNSs-PEG (PMGNSs) nanoparticles. The as-synthesized PMGNSs composed of a superparamagnetic Fe3O4 inner core, silica as the midlayer and coated with gold nanoshells at the outside, with uniform size distribution of less than 100 nm. It has been demonstrated to be with excellent magnetic resonance (MR) and computed tomography (CT) imaging contrast abilities at different concentrations. Meanwhile, the as-synthesized PMGNSs exhibited high stability with no significant change of photothermal performance after five laser ON/OFF cycles, and high photothermal conversion ability with temperature increase of 40 degrees C under 808 nm laser irradiation at 2 W cm(-2) for 10 min at the concentration of 160 mu g ml(-1). Furthermore, in vitro photothermal therapy ability has also been demonstrated on HePG2 cancer cells.